Arcus Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 577
- Market Cap
- -
- Website
- http://www.arcusbio.com
- Introduction
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06919991
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 610
- Registration Number
- NCT06608927
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇩🇪Krankenhaus Nordwest, Frankfurt am Main, Germany
🇮🇹Ospedale di Cremona, Cremona, Italy
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT06120075
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai/ The Tisch Cancer Center, New York, New York, United States
🇺🇸START - South Texas Accelerated Research Therapeutics, LLC., San Antonio, Texas, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06004921
- Locations
- 🇬🇧
Quotient Sciences - Nottingham, Nottingham, United Kingdom
A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05999513
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
- Conditions
- Bladder CancerAdvanced MalignanciesHead and Neck Squamous Cell Carcinoma (HNSCC)Advanced CancerEsophageal CancerGastric CancerNon-Small Cell Lung Cancer (NSCLC)Ovarian CancerRenal Cell Carcinoma (RCC)Triple Negative Breast Cancer (TNBC)
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT05891171
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Ronald Reagan UCLA Medical Center, Santa Monica, California, United States
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- Conditions
- Advanced Upper Gastrointestinal Tract Adenocarcinoma
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 1040
- Registration Number
- NCT05568095
- Locations
- 🇺🇸
UCLA Ronald Reagan Med Ctr, Santa Monica, California, United States
🇺🇸Smillow Cancer Hosp, New Haven, Connecticut, United States
🇺🇸Regions Hospital, Saint Louis Park, Minnesota, United States
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Conditions
- Solid TumorsClear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT05536141
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California at San Diego, San Diego, California, United States
🇺🇸Medical Oncology Associates Summit Cancer Centers, Spokane, Washington, United States
A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer
- Conditions
- Healthy Participants
- Interventions
- Drug: [14C]-etrumadenant
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05411146
- Locations
- 🇳🇱
PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen, NZ, Netherlands
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- Conditions
- Gastrointestinal Tract Malignancies
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT05329766
- Locations
- 🇫🇷
Institut Bergonié _ Bordeaux, Bordeaux, France
🇫🇷CHU de Brest_Brest, Brest, France
🇫🇷Centre Baclesse - CAEN, Caen Cedex 5, France